News

Implantica wins FDA approval for RefluxStop, opening the US market

Implantica has secured Premarket Approval (PMA) from the US Food and Drug Administration for RefluxStop, its implant-based treatment for gastroesophageal reflux disease (GERD), the Liechtenstein-based medtech company announced on 20 August 2026. The approval clears the way for a commercial launch in the United States, the world's largest medical device market.

Unlike acid-suppressing drugs, the CE-marked RefluxStop device is designed to treat the underlying cause of acid reflux by restoring the natural anti-reflux barrier at the lower oesophageal sphincter. The FDA granted the PMA following a full review that included long-term clinical evidence supporting five-year safety and effectiveness, with published outcomes reportedly showing around 90% improvement in symptom scores and pH levels.

RefluxStop already has several years of commercial experience in Europe, with close to 1,800 patients treated across more than 60 Centres of Excellence in nine European countries. Implantica said the initial US rollout will be targeted, focusing on selected leading centres and reflux surgeons, with adoption expected to build gradually as physician training and site activation progress. GERD affects an estimated 19% of the US and 17% of the EU population weekly.

Source: Implantica press release, 20 August 2026.

More top stories